Genmab A/S

Genmab A/S is a biotechnology company whose core business of developing antibody therapeutics requires animal testing as an integral part of its research and development process. The company acknowledges this reliance in its public Animal Welfare Policy, which states its operations are governed by the European Union's Directive 2010/63/EU on the protection of animals used for scientific purposes. This framework permits and standardizes the use of animals in laboratory research.

While the company asserts a commitment to the "highest ethical standards," its business model is fundamentally dependent on the commercial exploitation of animals for product testing and regulatory approval. As a developer of biologic drugs, Genmab's preclinical studies routinely utilize animals to assess the safety, efficacy, and pharmacokinetics of its drug candidates. This places the company's operations within the broad definition of animal exploitation for commercial gain, as the use of animals is not incidental but a necessary step in its value chain. The available evidence does not detail the scale or specifics of its animal use, but the policy framework it cites confirms the activity is a standard, regulated part of its business.